Beovu Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing amd prevalence, diabetic eye disease growth, early anti vegf adoption, ophthalmology clinic expansion, improved retinal diagnostics.

The growth in the forecast period can be attributed to aging global population, rising diabetes incidence, demand for durable therapies, improved retinal screening programs, outpatient treatment growth. Major trends in the forecast period include rising use of anti vegf therapies, preference for longer dosing intervals, growth of retinal disease treatment demand, expansion of outpatient ophthalmic care, focus on vision preservation in aging populations.

The rising incidence of retinal diseases is expected to drive the growth of the beovu market in the coming years. Retinal diseases are conditions that affect the retina, the light-sensitive tissue at the back of the eye, and include disorders such as age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment, and macular edema, often resulting in vision impairment. The increase in retinal diseases is driven by aging populations, rising diabetes rates, prolonged screen exposure, and genetic factors, leading to higher instances of vision loss and blindness. Beovu treats retinal diseases by inhibiting VEGF, reducing fluid leakage and retinal swelling, which helps improve vision, prevent disease progression, and enhance patient outcomes in conditions such as wet AMD and diabetic macular edema. For instance, the National Eye Institute, a U.S.-based government agency, reports that 2.7 million Americans currently live with glaucoma, a figure projected to rise to 4.3 million by 2030. Additionally, 7.7 million Americans are affected by diabetic retinopathy, with estimates rising to 11.3 million by 2030. Therefore, the increasing prevalence of retinal diseases is supporting growth in the beovu market.

The rising healthcare expenditure is expected to further propel the Beovu market. Healthcare expenditure refers to the total financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increase in healthcare spending is driven by the rising prevalence of chronic diseases, which require long-term and costly treatment. Higher healthcare expenditure supports Beovu adoption by expanding access to advanced ophthalmic therapies, improving availability for patients with retinal disorders such as AMD. It also enables investment in innovative biologic treatments, strengthening vision care and overall patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure increased by 5.6% in nominal terms in 2023, compared with 0.9% growth in 2022. Therefore, the rising healthcare expenditure is driving growth in the beovu market.

The growing geriatric population is expected to support the expansion of the Beovu market. The geriatric population consists of individuals aged 65 years and older, who often face age-related health, social, and functional changes. The increase in this population is attributed to factors such as improved healthcare, better living conditions, enhanced nutrition, and longer life expectancy. Beovu (brolucizumab) benefits the geriatric population by managing age-related macular degeneration (AMD), a leading cause of vision impairment in older adults, by reducing retinal fluid accumulation and helping stabilize or improve vision. For instance, in July 2024, the UK Parliament's House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older, representing 19% of the population, with projections suggesting this will rise to 22.1 million (27% of the population) by 2072. Therefore, the growing geriatric population is supporting the growth of the beovu market.

Major companies operating in the beovu market are Novartis AG.

North America was the largest region in the beovu market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the beovu market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the beovu market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the beovu market by increasing costs related to monoclonal antibody production, ophthalmic injection supplies, and refrigerated logistics. These impacts are most visible in hospital and specialty clinic procurement. Regions dependent on imported biologics face moderate pricing pressure. However, tariffs are promoting localized biologic fill and finish operations. This enhances long-term supply reliability and patient access.

The beovu market research report is one of a series of new reports that provides beovu market statistics, including beovu industry global market size, regional shares, competitors with a beovu market share, detailed beovu market segments, market trends and opportunities, and any further data you may need to thrive in the beovu industry. This beovu market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Beovu (brolucizumab) is a prescription medication used to treat certain eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This monoclonal antibody works by inhibiting vascular endothelial growth factor (VEGF-A), a protein involved in the formation of abnormal blood vessels in the eye, which can cause vision problems.

The primary indications for beovu include macular degeneration, diabetic retinopathy, and other related conditions. Macular degeneration affects the central part of the retina, known as the macula, leading to vision loss. It is a common cause of impaired vision in older adults and can progress to severe stages, particularly wet AMD, which may require treatments such as Beovu. The available dosage forms include gels, eye solutions, capsules, tablets, eye drops, and ointments. Beovu is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by end users including adults and geriatric patients.

The beovu market consists of sales of beovu vials, pre-filled syringes, multi-dose vials, and single-use injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.